Kurt R. Brekke (), Astrid L. Grasdal () and Tor Helge Holmås ()
Additional contact information
Kurt R. Brekke: Norwegian School of Economics and Business Administration, Department of Economics, Postal: Helleveien 30, N-5045 Bergen, Norway
Astrid L. Grasdal: University of Bergen, Department of Economics, Postal: Hermann Fossgt. 6, N-5007 Bergen, Norway
Tor Helge Holmås: Institute for Reasearch in Economics and Business Administration, Health Economic Bergen, Postal: Breiviksveien 40, N-5045 Bergen, Norway
Abstract: We study the relationship between regulatory regimes and pharmaceutical firms’ pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” for a sub-sample of off-patent pharmaceuticals, replacing the existing price cap (PC) regulation. We estimate the effect of the reform using a product level panel dataset, covering the drugs exposed to RP and a large number of drugs still under PC regulation in the time before and after the policy change. Our results show that RP significantly reduced both brand-name and generic prices within the reference group, with the effect being stronger for brand-names. We also identify a negative cross-price effect on therapeutic substitutes not included in the RP-system. In terms of policy implications, the results suggest that RP is more effective than PC regulation in lowering drug prices, while the cross-price effect raises a concern about patent protection.
Keywords: Pharmaceuticals; Price Regulation; Branded-Generic competition.
30 pages, September 19, 2006
Full text files
No.%2014-06.pdf Full text
Questions (including download problems) about the papers in this series should be directed to Kjell Erik Lommerud ()
Report other problems with accessing this service to Sune Karlsson ().
RePEc:hhs:bergec:2006_014This page generated on 2024-10-27 22:37:47.